Early First Cancer in BRCA1/2 Ups Risk in Opposite Breast

This article originally appeared here.
Share this content:
Early First Cancer in <i>BRCA1/2</i> Ups Risk in Opposite Breast
Early First Cancer in BRCA1/2 Ups Risk in Opposite Breast

TUESDAY, Dec. 29, 2015 (HealthDay News) -- BRCA1/2 mutation carriers have increased risk of contralateral breast cancer (CBC), with age at first diagnosis a significant predictor of CBC risk, according to a study published online Dec. 23 in the Journal of Clinical Oncology.

Alexandra J. van den Broek, from the Netherlands Cancer Institute in Amsterdam, and colleagues examined overall and age-specific estimates of CBC risk for young patients with breast cancer with or without BRCA1/2 mutations. Data were included for 6,294 patients with invasive breast cancer diagnosed under 50 years of age and treated between 1970 and 2003; participants were tested for the most prevalent BRCA1/2 mutations.

The researchers identified 578 CBCs in the study population after a median follow-up of 12.5 years. Compared with noncarriers, BRCA1 and BRCA2 mutation carriers had significantly increased CBC risk (hazard ratios, 3.31 and 2.17, respectively). The 10-year cumulative CBC risks were 21.1, 10.8, and 5.1 percent, respectively, for BRCA1 carriers, BRCA2 carriers, and noncarriers, respectively. In BRCA1/2 carriers only, age at diagnosis of first breast cancer was a significant predictor of CBC risk; the 10-year cumulative CBC risk was 23.9 percent in those diagnosed before age 41 years, compared with 12.6 percent for those aged 41 to 49 years (P = 0.02).

"Considering the available evidence, age-specific risk estimates should be included in counseling," the authors write.

One author disclosed financial ties to Agendia NV.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »